Golden Eye Antibiotic (Chloramphenicol)

Golden Eye Antibiotic is indicated for the treatment of bacterial infections of the eye surface. It is commonly prescribed when a clinician suspects or confirms bacterial conjunctivitis or other ocular infections caused by susceptible organisms.

• Bacterial conjunctivitis caused by susceptible strains of Staphylococcus, Streptococcus, Haemophilus, and Moraxella species.
• Acute bacterial keratitis when topical therapy is appropriate.
• Post‑operative prophylaxis of bacterial contamination after eye surgery.
• External ocular infections such as blepharitis or superficial corneal ulcers.
• Adjunctive therapy for mixed bacterial‑viral eye infections where bacterial component requires coverage.

The ocular use of chloramphenicol may be associated with a range of local and systemic adverse effects, although most are mild and reversible.

Common

• Transient eye irritation or burning sensation after instillation.
• Mild conjunctival redness or hyperemia.
• Temporary blurred vision that resolves within minutes.
• Mild eyelid edema.
• Slight increase in tear production or watery eyes.
• Mild itching of the eyelid margin.
• Temporary photophobia.

Serious

• Corneal epithelial toxicity leading to ulceration.
• Allergic contact dermatitis of the peri‑ocular skin.
• Rare systemic bone marrow suppression with prolonged use.
• Development of resistant bacterial strains with inappropriate use.
• Systemic adverse reactions such as nausea if absorbed in large amounts.

When prescribing Golden Eye Antibiotic, clinicians should consider several precautionary measures to minimize risks and ensure appropriate use.

• Verify that the ocular infection is bacterial and susceptible to chloramphenicol before initiating therapy.
• Avoid use in patients with a known hypersensitivity to chloramphenicol or other amphenicols.
• Limit treatment duration to the shortest effective period to reduce the chance of resistance.
• Exercise caution in patients with pre‑existing corneal epithelial defects or severe dry eye.
• Do not use in contact lens wearers unless lenses are removed and proper hygiene is maintained.
• Consider alternative agents in pregnant or nursing individuals due to limited safety data.

Chloramphenicol eye drops can interact with other ophthalmic or systemic agents, influencing efficacy or safety.

Avoid

• Concurrent use with other topical antibiotics that have overlapping spectra, as this may increase risk of resistance.
• Simultaneous administration of mydriatic or cycloplegic drops that could alter drug distribution on the ocular surface.

Use with caution

• Systemic aminoglycosides or other ototoxic drugs, because chloramphenicol may potentiate ototoxicity if absorbed.
• Topical corticosteroids, which may mask signs of infection and delay healing.
• Antifungal eye preparations, as combined use may affect corneal healing.
• Non‑steroidal anti‑inflammatory eye drops, as they may reduce chloramphenicol penetration.